NCT05760781View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

December 11, 2023

Study Completion Date

December 11, 2023

Conditions
Chronic Hepatitis b
Interventions
DRUG

STSG-0002 Injection

Intravenous infusion

Trial Locations (4)

100032

Peking University First Hospital, Beijing

100044

Peking University People's Hospital, Beijing

100069

Beijing Youan Hospital,Capital Medical, Beijing

401437

The Second Affiliated Hospital of Chongqing Medical, Chongqing

Sponsors
All Listed Sponsors
collaborator

Beijing Sanuo Jiayi Biotechnology Co. LTD

UNKNOWN

lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY